HUTCHMED DRC
Yahoo Finance • 8 days ago
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently devoid of approved... Full story
Yahoo Finance • 17 days ago
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Wei... Full story
Yahoo Finance • 29 days ago
Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma
(RTTNews) - HUTCHMED (HCM) and Innovent Biologics, Inc (HKEX:1801) said the China National Medical Products Administration (NMPA) has approved the combination of ELUNATE (fruquintinib) and TYVYT (sintilimab injection) for patients with loc... Full story
Yahoo Finance • 29 days ago
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801) today jointly announce that the New Drug... Full story
Yahoo Finance • 2 months ago
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, April 28, 2026 featuring live webcast presentations from international co... Full story
Yahoo Finance • 2 months ago
Agriculture, Construction, & Mining Machinery Industry Research Report 2026: Market to Reach $1.64 Trillion by 2032 - How Electrification and Telematics are Transforming Design
Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Agriculture, Construction, & Mining Machinery Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Agriculture, Construction, & Mining Machi... Full story
Yahoo Finance • 3 months ago
Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stor... Full story
Yahoo Finance • 3 months ago
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-7... Full story
Yahoo Finance • 3 months ago
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology... Full story
Yahoo Finance • 3 months ago
Hutchmed price target lowered to $21 from $22 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print “offered some positive steps forward after a weaker 1H25.” Directional... Full story
Yahoo Finance • 3 months ago
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has informed the Compan... Full story
Yahoo Finance • 4 months ago
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE N... Full story
Yahoo Finance • 4 months ago
HUTCHMED to Announce 2025 Final Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, Marc... Full story
Yahoo Finance • 6 months ago
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective MET inhibitor in China for MET-ampl... Full story
- AMG
Mentioned:
Yahoo Finance • 6 months ago
Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China
(RTTNews) - Hutchmed China Ltd. (HCM, HCM.L) announced Monday that the China National Medical Products Administration (NMPA) has accepted and granted priority review for New Drug Application or NDA for fanregratinib (HMPL-453) to treat adu... Full story
Yahoo Finance • 6 months ago
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison — HONG KONG and SHANGHAI and FLORHA... Full story
Yahoo Finance • 6 months ago
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (... Full story
Yahoo Finance • 6 months ago
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Sec... Full story
Yahoo Finance • 7 months ago
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by... Full story
Yahoo Finance • 7 months ago
HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM
In trading on Friday, shares of HUTCHMED (China) Ltd (Symbol: HCM) crossed below their 200 day moving average of $17.19, changing hands as low as $17.15 per share. HUTCHMED (China) Ltd shares are currently trading off about 1.6% on the da... Full story